Genetic risk factors of atherothrombosis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 9, 2014, Pages 474-482

  Montagnana, Martina ^a   Danese, Elisa ^a   Lippi, Giuseppe ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b ACADEMIC HOSPITAL OF PARMA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular disease; Genetics; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; C REACTIVE PROTEIN; GLYCOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

ARTERY THROMBOSIS; ATHEROGENESIS; BIOLOGICAL TRAIT; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HEMOSTASIS; HUMAN; INFLAMMATION; LIPID STORAGE; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); PATHOGENESIS; PHENOTYPIC VARIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; CAROTID ARTERY THROMBOSIS; CHOLESTEROL EMBOLISM; GENETIC PREDISPOSITION; GENETICS; LIPID METABOLISM; META ANALYSIS;

CAROTID ARTERY THROMBOSIS; EMBOLISM, CHOLESTEROL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIPID METABOLISM; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84907703880     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2409     Document Type: Review

References (109)

1. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011; 8: 502-512.
2. Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med. 2013; 12: 1-33.
3. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008; 451: 904-913.
4. Baigent C, Keech A, Kearney PM, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
5. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
6. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574.
7. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375: 1875-1884.
8. Gotto Jr AM, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol. 2012; 110: 15A-26.
9. Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008; 123: 15-33.
10. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008; 358: 1240-1249.
11. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008; 299: 2524-2532.
12. Haase CL, Tybjaerg-Hansen A, Grande P, et al. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab. 2010; 95: E50-E510.
13. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375: 1634-1639.
14. The CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013; 45: 25-33.
15. Shah S, Casas JP, Drenos F, et al. Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. Circ Cardiovasc Genet. 2013; 6: 63-72.
16. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2014 Jan 27. [Epub ahead of print].
17. Pandolfi A. C-reactive protein: a potential new molecular link between inflammation, thrombosis and vascular cell proliferation? Cardiovasc Res. 2005; 68: 3-4.
18. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004; 44: 6-11.
19. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109: 2058-2067.
20. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol. 2004; 24: 975-981.
21. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009; 38: 217-231.
22. Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013; 62: 397-408.
23. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008; 359: 1897-1908.
24. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009; 302: 37-48.
25. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342: d548.
26. Incalcaterra E, Accardi G, Balistreri CR, et al. Pro-inflammatory genetic markers of atherosclerosis. Curr Atheroscler Rep. 2013; 15: 329.
27. Durante A, Peretto G, Laricchia A, et al. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. 2012; 18: 981-1004.
28. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med. 2003; 163: 1155-1164.
29. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86: 1343-1346.
30. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992; 359: 641-644.
31. Samani NJ, Thompson JR, O'Toole L, et al. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996; 94: 708-712.
32. Bax WA, Dunser AH, Schalekamp MA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995; 92: 1387-1388.
33. Dakik HA, Mahmariian JJ, Verani MS, et al. Association of angiotensin-1-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct- related artery in patients with acute myocardial infarction. J Am Coll Cardiol. 1997; 29: 1468- 1473.
34. Doi Y, Yoshinari M, Yoshizumi H, et al. Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis. 1997; 132: 145-150.
35. Tiret L, Blanc H, Ruidavets JB, et al. Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Gènes de l'Hypertension Artérielle Sévère à modérée Essentielle. J Hypertens. 1998; 16: 37-44.
36. Kario K, Kanai N, Saito K, et al. Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation. 1996; 93: 1630-1633.
37. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease. Meta-analysis of small and large studies in whites. Arterioscler Thromb Vasc Biol. 2000; 20: 484-492.
38. Chen Y, Dong S, He M, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and risk of myocardial infarction in an updated meta-analysis based on 34 993 participants. Gene. 2013; 522: 196-205.
39. Wang S, Dai Y, Chen L, et al. Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies. PLoS One. 2013; 8: e75 285.
40. Yadav S, Hasan N, Marjot T, et al. Detailed analysis of gene polymorphisms associated with ischemic stroke in South Asians. PLoS One. 2013; 8: e57 305.
41. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, et al. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke. 2003; 34: 1634-1639.
42. Xu MQ, Ye Z, Hu FB, He L. Quantitative assessment of the effect of angiotensinogen gene polymorphisms on the risk of coronary heart disease. Circulation. 2007; 116: 1356-1366.
43. Liang X, Qiu J, Liu X, et al. Polymorphism of angiotensinogen gene M235T in myocardial infarction and brain infarction: a meta-analysis. Gene. 2013; 529: 73-79.
44. Liang B, Qin L, Wei H, et al. AGT M235T polymorphisms and ischemic stroke risk: a meta-analysis. J Neurol Sci. 2013; 331: 118-125.
45. Sui X, Gao C. The angiotensinogen gene M235T polymorphism and acute myocardial infarction risk: a meta-analysis of 22 studies. Mol Biol Rep. 2013; 40: 4439-4445.
46. Wang WZ. Association between T174M polymorphism in the angiotensinogen gene and risk of coronary artery disease: a meta-analysis. J Geriatr Cardiol. 2013; 10: 59-65.
47. Li X, Li Q, Wang Y, et al. AGT gene polymorphisms (M235T, T174M) are associated with coronary heart disease in a Chinese population. J Renin Angiotensin Aldosterone Syst. 2013; 14: 354-359.
48. Rubattu S, Di Angelantonio E, Stanzione R, et al. Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: a role of the A1166C/AT1 gene variant. J Hypertens. 2004; 22: 2129-2134.
49. Poirier O, Georges JL, Ricard S, et al. New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. J Hypertens. 1998; 16: 1443-1447.
50. Fatini C, Abbate R, Pepe G, et al. Searching for a better assessment of the individual coronary risk profile: the role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J. 2000; 21: 633-638.
51. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994; 24: 63-69.
52. Kretowski A, McFann K, Hokanson JE, et al. Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis. Diabetes. 2007; 56: 863-871.
53. Niu W, Qi Y. Association of the angiotensin II type I receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16 474 subjects. Hypertens Res. 2010; 33: 1137-1143.
54. Wang JL, Li Xue, Hao PP, et al. Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2010; 11: 127-135.
55. Xu M, Sham P, Ye Z, et al. A1166C genetic variation of the angiotensin II type I receptor gene and susceptibility to coronary heart disease: collaborative of 53 studies with 20,435 cases and 23,674 controls. Atherosclerosis. 2010; 213: 191-199.
56. Ji P, Jiang L, Zhang S, et al. Aldosterone synthase gene (CYP11B2)-344C/T polymorphism contributes to the risk of recurrent cerebral ischemia. Genet Test Mol Biomarkers. 2013; 17: 548-552.
57. Yan G, Wang Y. Association of CYP11B2 gene polymorphism with ischemic stroke in the north Chinese Han population. Neurol India. 2012; 60: 504-509.
58. Jia EZ, Xu ZX, Guo CY, et al. Renin-angiotensin-aldosterone system gene polymorphisms and coronary artery disease: detection of gene-gene and gene-environment interactions. Cell Physiol Biochem. 2012; 29: 443-452.
59. Munshi A, Sharma V, Kaul S, et al. Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hypertension and stroke. J Neurol Sci. 2010; 296: 34-38.
60. Payne JR, Dhamrait SS, Toor IS, et al. The -344T>C promoter variant of the gene for aldosterone synthase (CYP11B2) is not associated with cardiovascular risk in a prospective study of UK healthy men. Atherosclerosis. 2004; 174: 81-86.
61. Kikuya M, Sugimoto K, Katsuya T, et al. A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: the Ohasama Study. Hypertens Res. 2003; 26: 141-145.
62. Clemetson KJ. Platelet receptors and their role in diseases. Clin Chem Lab Med. 2003; 41: 253-260.
63. Lippi G, Montagnana M, Danese E, et al. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Biomark Med. 2011; 5: 63-70.
64. Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol. 2001; 5: 262-287.
65. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol. 2000; 86: 1000-1005.
66. Di Castelnuovo A, de Gaetano G, Donati MB, et al. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost. 2001; 85: 626-633.
67. Galasso G, Santulli G, Piscione F, et al. The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events. BMC Cardiovasc Disord. 2010; 10: 41.
68. Pellitero S, Reverter JL, Tàssies D, et al. Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes. Thromb Haemost. 2010; 103: 630-637.
69. Kucharska-Newton AM, Monda KL, Campbell S, et al. Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2011; 216: 151-156.
70. Verdoia M, Cassetti E, Schaffer A, et al; on behalf of the Novara Atherosclerosis Study Group (NAS). Relationship Between Glycoprotein IIIa Platelet Receptor Gene Polymorphism and Coronary Artery Disease. Angiology. 2014 Feb 28. [Epub ahead of print].
71. Verdoia M, Pergolini P, Camaro C, et al Novara Atherosclerosis Study Group (NAS). PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis. 2013; 24: 411-418.
72. Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol. 2001; 5: 262-287.
73. Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis. 2008; 196: 341-348.
74. Carlsson LE, Santoso S, Spitzer C, et al The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999; 93: 3583-3586.
75. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis. Int J Cardiol. 2007; 118: 189-196.
76. Nikolopoulos GK, Tsantes AE, Bagos PG, et al. Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Thromb Res. 2007; 119: 501-510.
77. Wu G, Xi Y, Yao L, et al. Genetic polymorphism of ITGA2 C807T can increase the risk of ischemic stroke. Int J Neurosci. 2014 Feb 13. [Epub ahead of print].
78. Croft SA, Samani NJ, Hampton KK, et al. Novel platelet membrane glycoprotein VI dipolymorphism is a risk factor for myocardial infarction. Circulation. 2001; 104: 1495-1563.
79. Ollikainen E, Mikkelsson J, Perola M, et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis. 2004; 176: 95-99.
80. Takagi S, Iwai N, Baba S, et al. A GPVI polymorphism is a risk factor for myocardial infarction in Japanese. Atherosclerosis. 2002; 165: 397-398.
81. Gonzalez-Conejero R, Lazono ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease. Blood. 1998; 92: 2771-2776.
82. Carter AM, Catto AJ, Bamford JM, et al. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Artioscler Thromb Vasc Biol. 1998; 7: 1124-1131.
83. Sonada A, Murata M, Ito D, et al. Association between platelet glycoprotein 1bα genotype and ischemic cerebrovascular disease. Stroke. 2000; 31: 493-497.
84. Mikkelsson J, Perola M, Penttilä A, et al. Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation. 2001; 104: 876-880.
85. Baker RI, Eikelboom J, Lofthouse E, et al. Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood. 2001; 98: 36-40.
86. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, et al. Kozak sequence polymorphism of the glycoprotein (GP) 1bα gene is a major determinant of the plasma membrane levels of the platelet GP 1b-IX-V complex. Blood. 1999; 94: 186-191.
87. Siscovick DS, Schwartz SM, Rosendaal FR, et al. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost. 1997; 78: 7-12.
88. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005; 25: 2043-2053.
89. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997; 89: 2817-282.
90. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20 210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997; 90: 1747-1750.
91. Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost. 2007; 33: 588-596.
92. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332: 912-917.
93. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999; 94: 46-51.
94. Cushman M, Rosendaal FR, Psaty BM, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost. 1998; 79: 912-915.
95. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol. 2001; 87: 1361-1366.
96. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006; 367: 651-658.
97. Forte GI, Vaccarino L, Palmeri M, et al. Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction. Biogerontology. 2011; 12: 485-490.
98. Boroumand M, Pourgholi L, Ziaee S, et al. The association between Factor V Leiden with the presence and severity of coronary artery disease. Clin Biochem. 2014; 47: 356-360.
99. Bozzini C, Girelli D, Bernardi F, et al. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thromb Haemost. 2004; 92: 541-549.
100. Rubattu S, Di Angelantonio E, Nitsch D, et al. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Haemost. 2005; 93: 1095-1100.
101. Maguire JM, Thakkinstian A, Sturm J, et al. Polymorphisms in platelet glycoprotein 1balpha and factor VII and risk of ischemic stroke: a meta-analysis. Stroke. 2008; 39: 1710-1716.
102. Dawson S, Hamsten A, Wiman B, et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991; 11: 183-190.
103. Iacoviello L, Burzotta F, Di Castelnuovo A et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80: 1029-1030.
104. Ridker PM, Hennekens CH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997; 95: 59-62.
105. Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost. 2003; 1: 1799-1804.
106. Nikolopoulos GK, Bagos PG, Tsangaris I, et al. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clin Chem Lab Med. 2014; 52: 937-950.
107. Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. In: Meeting the Challenges in Developing Countries; Fuster V, Kelly BB, eds. Washington, DC: National Academies Press (US); 2010.
108. Epstein FH. Genetics of ischaemic heart disease. Postgrad Med J. 1976; 52: 477-480.
109. García-Giménez JL, Sanchis-Gomar F, Lippi G, et al. Epigenetic biomarkers: a new perspective in laboratory diagnostics. Clin Chim Acta. 2012; 413: 1576-1582.